JPWO2022059691A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022059691A5 JPWO2022059691A5 JP2023516473A JP2023516473A JPWO2022059691A5 JP WO2022059691 A5 JPWO2022059691 A5 JP WO2022059691A5 JP 2023516473 A JP2023516473 A JP 2023516473A JP 2023516473 A JP2023516473 A JP 2023516473A JP WO2022059691 A5 JPWO2022059691 A5 JP WO2022059691A5
- Authority
- JP
- Japan
- Prior art keywords
- oxadiazol
- sulfamoyl
- dimethylphenyl
- benzamide
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078833P | 2020-09-15 | 2020-09-15 | |
| US63/078,833 | 2020-09-15 | ||
| PCT/JP2021/033854 WO2022059691A1 (en) | 2020-09-15 | 2021-09-15 | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541430A JP2023541430A (ja) | 2023-10-02 |
| JPWO2022059691A5 true JPWO2022059691A5 (https=) | 2024-08-14 |
| JP2023541430A5 JP2023541430A5 (https=) | 2024-08-14 |
Family
ID=80776688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516473A Pending JP2023541430A (ja) | 2020-09-15 | 2021-09-15 | リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230338342A1 (https=) |
| EP (1) | EP4213841A4 (https=) |
| JP (1) | JP2023541430A (https=) |
| KR (1) | KR20230067646A (https=) |
| AU (1) | AU2021344091A1 (https=) |
| WO (1) | WO2022059691A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130005678A1 (en) * | 2010-03-30 | 2013-01-03 | Clavis Pharma Asa | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate |
| US10889555B2 (en) * | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
| US20200405697A1 (en) * | 2017-11-29 | 2020-12-31 | Taiho Pharmaceutical Co., Ltd. | Antitumor Agent |
-
2021
- 2021-09-15 US US18/044,978 patent/US20230338342A1/en active Pending
- 2021-09-15 WO PCT/JP2021/033854 patent/WO2022059691A1/en not_active Ceased
- 2021-09-15 JP JP2023516473A patent/JP2023541430A/ja active Pending
- 2021-09-15 EP EP21869377.8A patent/EP4213841A4/en active Pending
- 2021-09-15 KR KR1020237012412A patent/KR20230067646A/ko active Pending
- 2021-09-15 AU AU2021344091A patent/AU2021344091A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023041862A5 (https=) | ||
| ES2256913T3 (es) | Antagonistas de arginina para la inhibicion de la hipotension sistemica asociada a la produccion de oxido nitrico o al factor de relajacion derivado endotelial. | |
| Saadeh | Chemotherapy‐and radiotherapy‐induced oral mucositis: Review of preventive strategies and treatment | |
| ES2260906T3 (es) | Tratamiento de hipertension iatrogenica y relacionada con la edad con derivados de vitamina b6 y composiciones farmaceuticas utiles en el mismo. | |
| CN104918613B (zh) | 通过给予秋水仙碱衍生物治疗或预防心血管事件 | |
| JP2022180461A5 (https=) | ||
| JPS61501393A (ja) | ジフェンヒドラミン類を含んで成る鎮痛および抗炎症組成物 | |
| TW200306799A (en) | Combination of organic compounds | |
| JPWO2022059691A5 (https=) | ||
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| JPWO2022059692A5 (https=) | ||
| US20050020657A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 | |
| JP2021522246A5 (https=) | ||
| TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
| Wong | Oral bexarotene in the treatment of cutaneous T-cell lymphoma | |
| JP2022177119A5 (https=) | ||
| ES2348140T3 (es) | Combinación de un análogo de mostaza nitrogenada y de imatinib para el tratamiento de la leucemia linfocítica crónica. | |
| IL292882A (en) | Dosage of Bruton's tyrosine kinase inhibitor | |
| WO2001000196A2 (en) | Mirtazapine for weight gain in wasting diseases | |
| US6620816B2 (en) | Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide | |
| RU2023109542A (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| ES2281775T3 (es) | Metodo para tratar insuficiencia renal. | |
| JPWO2019211721A5 (https=) | ||
| CN1537006A (zh) | 含有米尔塔扎平和对乙酰氨基酚或一种非甾类消炎药的用于治疗头痛的联合用药物 | |
| Durivage et al. | Prevention and management of toxicities associated with antineoplastic drugs |